公开(公告)号：US20230355582A1

公开(公告)日：2023-11-09

申请号：US18355618

申请日：2023-07-20

Applicant: NOVARTIS AG

Inventor： Bruno GALLI ,  Jean-Marie GLANTZMANN ,  Arnaud GRANDEURY ,  Klaus-Peter MOLL ,  Martin MUELLER-ZSIGMONDY ,  Karsten PUTZBACH ,  Dirk SPICKERMANN ,  Hubert THOMA ,  Mike UFER

IPC: A61K31/404 ,  A61K9/28 ,  A61K9/20 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/16 ,  A61K9/50 ,  A61K47/38

CPC classification number: A61K31/404 ,  A61K9/28 ,  A61K9/2004 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/2072 ,  A61K9/50 ,  A61K9/5089 ,  A61K47/38

Abstract: Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,45,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

公开(公告)号：US20210069150A1

公开(公告)日：2021-03-11

申请号：US16898071

申请日：2020-06-10

Applicant: NOVARTIS AG

Inventor： Bruno GALLI ,  Jean-Marie GLANTZMANN ,  Arnaud GRANDEURY ,  Klaus-Peter MOLL ,  Martin MUELLER- ZSIGMONDY ,  Karsten PUTZBACH ,  Dirk SPICKERMANN ,  Hubert THOMA ,  Mike UFER

IPC: A61K31/404 ,  A61K9/28 ,  A61K9/20 ,  A61K31/4045 ,  A61J3/02 ,  A61J3/10 ,  A61K9/16 ,  A61K9/50 ,  A61K47/38

Abstract: Drug products in the form of modified release formulations comprising the drug substance (−)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia.

公开(公告)号：US20210015804A1

公开(公告)日：2021-01-21

申请号：US16929472

申请日：2020-07-15

Applicant: NOVARTIS AG

Inventor： Vivek DUBEY ,  Rohit LOWALEKAR ,  Paulo G. SANTOS ,  Hubert THOMA ,  Xianbin TIAN

IPC: A61K31/44 ,  A61K9/20 ,  A61K9/28

Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating bronchiectasis, chronic obstructive pulmonary disorder, cystic fibrosis, chronic bronchitis or asthma comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition described herein.